Teva Says Fed. Circ. Made Skinny Label Law 'A Dead Letter'
The Federal Circuit rendered a section of the Hatch-Waxman Act that allows generic-drug makers to sell patent-protected drugs for unpatented uses "a dead letter" when it revived GlaxoSmithKline's $235 million induced...To view the full article, register now.
Already a subscriber? Click here to view full article